Factors Influencing Final/Near-Final Height in 12 Boys with Central Precocious Puberty Treated with Gonadotrophin-Releasing Hormone Agonists

Rizzo, V.; Sanctis, Vincenzo De; Corrias, Andrea; Fortini, Monica; Galluzzi, F.; Bertelloni, Silvano; Guarneri, Maria Pia; Pozzan, Giovanni Battista; Cisternino, Mariangela; Pasquino, A. M.

doi:10.1515/jpem.2000.13.s1.781

Cited by 20 publications

(20 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This rate is one of the lowest rates in the literature. Similar to the present study, Rizzo et al [3] found that an underlying organic cause was present in 25% of the cases; however, while Rizzo et al [3] evaluated only 12 male CPP cases, in the present study, 100 male cases were evaluated, which makes this study one of the most comprehensive studies with respect to the number of cases. The study by De Sanctis et al [15], which included 45 cases, found that the incidence of organic cases was 40%, while this rate is 48.7% in the review by Pigneur et al [16].…”

Section: Discussionsupporting

confidence: 74%

“…According to these studies, the prevalence of an underlying organic cause in male CPP cases has been reported to range between 73 and 94% [1,2]. On the other hand, studies after the year 2000 have reported a wide range for the prevalence of male organic CPP cases (25-83%) [3,4,5,6]. The number of cases in most of these studies is considerably low as they include only 10-20 cases.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Changing Etiological Trends in Male Precocious Puberty: Evaluation of 100 Cases with Central Precocious Puberty over the Last Decade

et al. 2015

View full text Add to dashboard Cite

Background/Aims: There are few studies in the literature that have evaluated the etiological factors in boys with central precocious puberty (CPP), and these studies are limited in terms of the sample size. In the present study, we aimed to evaluate the etiological factors in male CPP cases. Methods: One hundred male CPP subjects, aged between 9 months and 10.5 years, were included. The medical records were screened, and age at diagnosis, bone age, body weight, height, pubertal stage, imaging findings of the pituitary gland, testosterone, and basal and stimulated gonadotropin levels were recorded. Results: There was no underlying cause in 74% of the cases, and an organic cause was determined in only 26%. Most of the organic cases had been diagnosed before the age of 7 years, whereas most of the idiopathic cases had been diagnosed after the age of 7 years. Conclusion: An organic cause was determined in 26% of the male patients with CPP. This rate is one of the lowest rates in the literature and indicates that the number of idiopathic male CPP cases is increasing over time. When a boy is diagnosed with CPP above the age of 7 years, the odds of detecting an underlying pathology are very low, and these cases are mostly idiopathic.

show abstract

Section: Discussionsupporting

confidence: 74%

Section: Introductionmentioning

confidence: 99%

Changing Etiological Trends in Male Precocious Puberty: Evaluation of 100 Cases with Central Precocious Puberty over the Last Decade

et al. 2015

View full text Add to dashboard Cite

show abstract

“…In normal children, peak height velocity occurs around a CA of 11.5 years in girls and 13.5 years in boys [26]. In several studies in girls with CPP the average BA at interruption of treatment was 112 years [1,2,6,24] while it is close to 13.5 years in boys [6,27, and this study]. Therefore BA at discontinuation corresponds to early mid-puberty in boys and to late puberty in girls.…”

Section: Discussionsupporting

confidence: 63%

Effect of Gonadotropin-Releasing Hormone Agonist Treatment in Boys with Central Precocious Puberty: Final Height Results

et al. 2002

Self Cite

View full text Add to dashboard Cite

Objective: The small number of boys present in most studies on final height (FH) after gonadotropin-releasing hormone agonist (GnRHa) treatment for central precocious puberty (CPP) offers difficulties in the evaluation of the effects of treatment on FH in males. Method: We therefore combined FH data from The Netherlands, Italy and France to study the effect of GnRHa treatment in a large group of 26 boys with CPP. Results: The mean chronological age at the start of treatment was 7.6 ± 2.0 (SD) years, bone age (BA) was 11.0 ± 2.1 years. All boys were treated with depot formulations of the GnRHa triptorelin with established gonadal suppression for a mean treatment period of 4.7 ± 2.1 years. FH was 172.9 ± 6.6 cm. FH standard deviation score (SDS) was –0.66 ± 1.22, not significantly different from the target height SDS of –0.23 ± 0.75. FH-SDS was significantly lower in the subgroup of 12 patients with organic CPP compared to patients with idiopathic CPP (–1.34 ± 1.06 vs. –0.08 ± 1.06, respectively; p = 0.01), but no difference in height gain was observed. The mean estimated height gain, defined as the difference between predicted and actual adult height was 6.2 ± 8.7 cm using the average tables of Bayley and Pinneau, and 0.3 ± 8.6 cm using the BA advance adjusted tables. Regional differences in height gain were observed between the different countries, reflecting different local practices. Conclusion: We conclude that GnRHa treatment in boys results in a FH close to target height.

show abstract

“…In addition, other studies have demonstrated improvement of growth prognosis and restoration of genetic height potential in boys with progressive GDPP treated exclusively with GnRH analog (28,29). In our study a small number of boys was analyzed, and eight of the nine boys (89%) reached their TH range.…”

Section: Discussionmentioning

confidence: 75%

Factors Determining Normal Adult Height in Girls with Gonadotropin-Dependent Precocious Puberty Treated with Depot Gonadotropin-Releasing Hormone Analogs

Brito

Latrônico

Cukier

et al. 2008

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

show abstract

Factors Influencing Final/Near-Final Height in 12 Boys with Central Precocious Puberty Treated with Gonadotrophin-Releasing Hormone Agonists

Cited by 20 publications

References 0 publications

Changing Etiological Trends in Male Precocious Puberty: Evaluation of 100 Cases with Central Precocious Puberty over the Last Decade

Changing Etiological Trends in Male Precocious Puberty: Evaluation of 100 Cases with Central Precocious Puberty over the Last Decade

Effect of Gonadotropin-Releasing Hormone Agonist Treatment in Boys with Central Precocious Puberty: Final Height Results

Factors Determining Normal Adult Height in Girls with Gonadotropin-Dependent Precocious Puberty Treated with Depot Gonadotropin-Releasing Hormone Analogs

Contact Info

Product

Resources

About